UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 18, 2020

IMMUNOMEDICS, INC.

(Exact name of registrant as specified in its charter)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02            Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As disclosed under Item 5.07 of this Current Report on Form 8-K, at the Annual Meeting of Stockholders (the “Annual Meeting”) of Immunomedics, Inc. (the “Company”), the stockholders of the Company voted to approve the Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan (the “Amended 2014 Plan”).

The Amended 2014 Plan is described in greater detail in the Company’s Definitive Proxy Statement on Schedule 14A (the “Proxy Statement”), filed with the United States Securities and Exchange Commission (“SEC”) on April 27, 2020, under the heading “Proposal Four: Approval of the Immunomedics, Inc. Amended and Restated 2014 Long-Term Incentive Plan - Summary of Amended 2014 Plan,” which description is incorporated by reference herein.

The foregoing summary of the Amended 2014 Plan is qualified in its entirety by reference to the full text of the Amended 2014 Plan, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 5.03            Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

As disclosed under Item 5.07 of this Current Report on Form 8-K, on June 18, 2020, the stockholders of the Company voted at the Annual Meeting to approve the amendment and restatement of the Company’s certificate of incorporation to increase the maximum number of authorized shares of the Company's capital stock, all classes, from 260,000,000 shares, consisting of (i) 250,000,000 shares of common stock, $0.01 par value per share (“Common Stock”), and (ii) 10,000,000 shares of preferred stock, $0.01 par value per share (“Preferred Stock”), to 285,000,000 shares, consisting of (x) 275,000,000 shares of Common Stock, and (y) 10,000,000 shares of Preferred Stock (such amended and restated certificate of incorporation, the “Restated Certificate”). Subsequent to such approval, on June 18, 2020, the Company filed the Restated Certificate with the Secretary of State of the State of Delaware.

The foregoing summary of the Restated Certificate is qualified in its entirety to the full text of the Restated Certificate, which is filed as Exhibit 3.1 hereto and is incorporated herein by reference.

Item 5.07            Submission of Matters to a Vote of Security Holders.

The Annual Meeting was held at the Company’s executive offices, 410 The American Road, Morris Plains, New Jersey, on Thursday, June 18, 2020. At the Annual Meeting, the following matters were submitted to a vote of stockholders:

At the close of business on April 24, 2020, the record date for the determination of stockholders entitled to vote at the Annual Meeting, there were 213,945,493 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. The holders of 191,257,095 shares of the Company’s common stock were represented in person or by proxy at the Annual Meeting, constituting a quorum.

With respect to the election of the director nominees to serve until the 2021 Annual Meeting of Stockholders, the votes were as follows:

The non-binding advisory votes with respect to approval of the compensation of the Company’s named executive officers were as follows:

With respect to the approval of the Restated Certificate, the votes were as follows:

With respect to the amendment and restatement of the Company’s 2014 Long-Term Incentive Plan, the votes were as follows:

With respect to the approval and adoption of the Company’s 2020 Employee Stock Purchase Plan, the votes were as follows:

With respect to the ratification of the Company’s appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020, the votes were as follows:

The foregoing votes reflect that all of the director nominees were elected to serve until the 2021 Annual Meeting of Stockholders; the Restated Certificate was approved; the amendment and restatement of the Company’s 2014 Long-Term Incentive Plan was approved; the adoption of the Company’s 2020 Employee Stock Purchase Plan was approved; the compensation of the Company’s named executive officers was approved by non-binding advisory votes; and KPMG LLP was ratified as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. 

Item 9.01 Financial Statements and Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.